11:31 AM EST - Microbix Biosystems Inc. : Reports results for its fiscal year and fourth quarter ended September 30, 2024. 2024 revenues were $25,394,148, a significant increase from fiscal 2023 revenues of $16,514,776. Increased sales in our Antigen and QAPs businesses, increased Kinlytic licensing fees, and higher gross margin dollars led to an operating income (before finance expenses and income taxes) of $3,905,011 and a net income of $3,520,179 versus a 2023 operating loss of $2,736,432 and net loss of $39,483. Microbix Biosystems Inc.
shares T.MBX are trading up $0.0-2 at $0.38.
